Abbott Labs (ABT) Reporting Earnings Before The Bell – What To Expect

Abbott Laboratories stock (NYSE: ABT) would expect to see some movement this morning, with earnings coming before the bell usually a notable period of volatility for any company's shares. The gain of 0.39% for ABT in the pre-market negates some of yesterday's bearish market momentum, and comes as markets gear up for a fresh set of numbers to digest.

The subtle downturn in Abbott's stock price during the regular session reflects largely on the pullback in the broader market, with the stock currently trading up 5.64% on a YTD basis, and nearer the upper end of its 52-week range, which spans from $90.87 to $121.64.

Abbott has a recently history of beating earnings consensus, both on EPS and revenues, with the last four periods each coming in above expectations. More growth is expected for the upcoming report, with the consensus marks on revenue expected at $10.55B against an earnings per share of $1.20.

For comparison, the actuals from the previous quarter came in with revenue of 10.38B, against an EPS of $1.14.

In the broader Healthcare and Medical Devices markets, advancements in technology and an aging population are careful considerations impacting companies like Abbott. Standing at the forefront of medical innovation and positioned well due to its diversified product range and established market presence, Abbott Laboratories is anticipated to remain a key player, navigating through regulatory challenges and market competition effectively.

Founded in 1888 and headquartered in North Chicago, Illinois, Abbott Laboratories operates within the Healthcare sector, particularly in the Medical Devices industry. The company's comprehensive portfolio of health care products is recognized worldwide, with operations segmented into Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. These segments encompass a diverse range of items from generic pharmaceuticals to advanced medical devices for cardiovascular conditions and diabetes care products.

As of the latest figures, Abbott Laboratories boasts a market cap of $202.49 billion, indicating its significant presence in the market. Financially, Abbott is characterized by a trailing P/E ratio of 36.71 and a more forward-looking P/E ratio of 22.64. This disparity suggests investors may have optimism for its future earnings potential. The company supports a dividend rate of $2.20 with a yield of 1.88%, marked by a payout ratio of 66.88%. Overall, Abbott has generated total revenue of $40.73 billion with a net income to common of $5.54 billion, underscoring its strong financial health.

Analysts have a bullish consensus on the stock, setting a mean price target of $125.70 and maintaining a buy recommendation. Twenty-four analysts have weighed in on the share outlook, reiterating a general sentiment of confidence in Abbott's market positioning and prospects.

As Abbott Laboratories steers towards the revelation of its upcoming earnings, the market's tempered response so far suggests a wait and see approach.